Lakewood-Amedex Biotherapeutics 已向美国证券交易委员会提交文件,宣布对其已发行的普通股进行一比十的反向股票分割。
此项公司行动旨在调整其股本结构。反向拆股预计将于近期生效,具体细节请参阅公司提交的正式监管文件。
Lakewood-Amedex Biotherapeutics 已向美国证券交易委员会提交文件,宣布对其已发行的普通股进行一比十的反向股票分割。
此项公司行动旨在调整其股本结构。反向拆股预计将于近期生效,具体细节请参阅公司提交的正式监管文件。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.